Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May;31(3):404-410.
doi: 10.1111/pcmr.12675. Epub 2017 Dec 7.

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma

Jenny H J Lee  1   2   3 , Megan Lyle  2   4   5 , Alexander M Menzies  2   4   6 , Matthew M K Chan  7 , Serigne Lo  2   4 , Arthur Clements  8   9 , Matteo S Carlino  2   3   4 , Richard F Kefford  1   2   3   4 , Georgina V Long  2   4   6
Affiliations
Clinical Trial

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma

Jenny H J Lee et al. Pigment Cell Melanoma Res. 2018 May.

Abstract

This study evaluated patterns of response as discerned by comprehensive metastasis-specific analysis in metastatic melanoma patients receiving anti-PD-1 antibodies. Bi-dimensional measurements of every metastasis in patients enrolled in the KEYNOTE-001 trial at a single institution were obtained at baseline and throughout treatment. Twenty-seven evaluable patients had 399 baseline metastases measurable on CT imaging. Complete response (CR) which occurred in 52.6% of metastases was smaller (mean 223 mm2 versus 760 mm2 , p < .01) and occurred more frequently in the lungs (65% versus 39.4%, p < .01). Response was heterogenous (new/progressing metastases alongside CR metastases) at first assessment in 4/14 patients with objective response (OR) as opposed to 7/13 patients with non-OR. CR of individual metastases is common and influenced by site and size. Most patients with OR demonstrate homogenous regression in all metastases at the first assessment. In contrast, patients with early heterogeneity had a poor outcome.

Keywords: immune-related response criteria; immunotherapy; melanoma; pembrolizumab; programmed-death receptor 1.

PubMed Disclaimer

Publication types